Modified luciola cruciata luciferase protein

ABSTRACT

A codon optimized and stabilized luciferase gene based upon the sequence of the natural luciferase gene isolated from  Luciola cruciata  (Japanese firefly) and a novel recombinant DNA characterized by incorporating this new gene coding for a novel luciferase into a vector DNA for improved activities in mammalian cells, are disclosed. This new luciferase exhibits long-wavelength light emission, as well as improved thermostability and higher expression levels in mammalian cell systems, compared to native luciferase.

FIELD OF THE INVENTION

The present invention relates to a novel codon optimized and stabilized luciferase gene (COS luciferase) derived from Japanese firefly Luciola cruciata luciferase. The invention further relates to production of a stabilized luciferase protein using such a modified gene.

BACKGROUND OF THE INVENTION

Bioluminescence in certain organisms via the reaction of luciferin and luciferase is well known in the art. The use of the luciferase enzyme has become highly valuable as a genetic marker gene due to the convenience, sensitivity and linear range of the luminescence assay. Luciferase has been used in many experimental biological systems in both prokaryotic and eukaryotic cell culture, transgenic plants and animals, as well as cell-free expression systems.

For example, Japanese Firefly Luciola cruciata luciferase expression can be monitored as a genetic marker in cell extracts when mixed with substrates (D-luciferin, Mg²⁺ ATP, and O₂), and the resulting luminescence measured using a luminescent detection device (containing a photomultiplier system or equivalent) such as liminometers or scintillation counters without the need of a reagent injection device. The Luciola cruciata luciferase activity can also be detected in living cells by adding D-luciferin or more membrane permeant analogs such as D-luciferin ethyl ester to the growth medium. This in vivo luminescence relies on the ability of D-luciferin or more membrane permeant analogs to diffuse through cellular and intracellular organelle membranes and on the intracellular availability of ATP and O₂ in these cells.

Despite its utility as a reporter, current luciferases isolated from various organisms, including insects and marine organisms are not necessarily optimized for expression or production in systems that are of most interest to the medical community and experimental molecular biologists. Accordingly, a need exists for a luciferase nucleic acid molecule that allows improved protein production in mammalian cells and tissues.

SUMMARY OF THE INVENTION

The present invention describes a novel codon optimized and stabilized luciferase gene coding for an improved luciferase protein. This new luciferase exhibits long-wavelength light emission, as well as improved thermostability and higher expression levels in mammalian cell systems, compared to native luciferase. Also described is a method of producing a stabilized luciferase protein by inserting a nucleic acid molecule of the present invention into an appropriate microorganism via a vector and culturing the microorganism to produce the stabilized luciferase protein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a cleavage map of recombinant plasmid pDC57 DNA with endonuclease restriction enzymes.

FIG. 2 shows a cleavage map of recombinant plasmid pDC99 DNA with endonuclease restriction enzymes.

FIG. 3 shows a comparison of the native L. cruciata luciferase sequence with the codon optimised nucleotide sequence of the present invention.

FIG. 4 shows a comparison of Luciferase Expression Levels using the pDC99 vector of the present invention with the Photinus pyralis luciferase vector pSV40-GL3 in mammalian cells.

FIG. 5 shows a comparison of the thermal stability of the modified Luciola cruciata luciferase protein of the present invention with that of the Photinus pyralis wild type protein.

DETAILED DESCRIPTION OF THE INVENTION

The wild-type sequence is known for the luciferase molecule from many different species and numerous modifications to those sequences have been described in the art. The present invention describes modifications to the nucleic acid molecule encoding luciferase in the Japanese firefly, Luciola cruciata as well as the luciferase protein itself. In a particular embodiment of the invention, the modified Luciola cruciata luciferase nucleic acid molecule encodes an improved luciferase enzyme which demonstrates greater thermostability (see FIG. 5 for an analysis of the thermal stability of the codon-optimized and stabilized Luciola cruciata luciferase protein of the present invention versus wild type protein at various temperatures) as well as a wavelength shift from blue to red compared to native luciferase.

In another embodiment of the present invention, mRNA transcribed from the modified luciferase nucleic acid molecule is more stable in mammalian cells. This leads to enhanced levels of mRNA and results in greater expression of the luciferase (see FIG. 4 for a comparison of expression levels using the pDC99 vector of the present invention with the Photinus pyralis luciferase vector pSV40-GL3 in mammalian cells). In another embodiment, the level of mRNA is preferably increased by 10% to 200% over that seen when native sequence is expressed in mammalian cells.

In a particular embodiment of the present invention, the modified Luciola cruciata luciferase nucleic acid molecule is altered to remove RNAse cleavage motifs. The wild-type sequence shown in SEQ ID NO:1 has RNAse cleavage motifs at nucleotides 384-388, 682-686, and 929-933. In a preferred embodiment, the modified sequence is changed as shown in SEQ ID NO:3 and FIG. 3 to remove these motifs. In particular, nucleotides 384 to 388 are changed from (ATTTA) to GTTCA, nucleotides 682 to 686 are changed from (ATTTA) to ATCTA and nucleotides 929 to 933 are changed from ATTTA) to ACCTG.

Vectors such as retroviral vectors or other vectors intended for the introduction of recombinant DNA into mammalian cells will often contain active splice donor sequences. Instability is often created when a wild type gene from a non-mammal is carried by a retroviral vector due to the recognition of cryptic splice acceptor sequences in the wild type gene and splicing between these and splice donor sites present in the vector. In a particular embodiment of the present invention, cryptic splice acceptor sequences present in the wild type L. cruciata luciferase nucleic acid molecule are altered or removed.

In another particular embodiment of the present invention, cryptic splice acceptor sites found at bases 448 to 463, 919 to 934, 924 to 939, 940 to 955, 1148 to 1163, 1156 to 1171, 1159 to 1174, and 1171 to 1186 of the wild type sequence of SEQ ID NO:1 have one or more nucleotides altered. In a particular embodiment, bases 448 to 463 of the wild type L. cruciata luciferase, i.e. ACCATTGTTATACTAG, herein SEQ ID NO:5 are changed in the COS luciferase to ACCATCGTGATCCTGG herein SEQ ID NO:6.

In another embodiment, bases 919 to 934 of the wild type L. cruciata luciferase, i.e. GATTTGTCAAATTTAG herein SEQ ID NO:7 are changed in the COS luciferase to GACCTGAGCAACCTGG herein SEQ ID NO:8.

In another embodiment, bases 924 to 939 of the wild type L. cruciata luciferase, i.e. GTCAAATTTAGTTGAG herein SEQ ID NO:9 are changed in the COS luciferase to GAGCAACCTGGTGGAG herein SEQ ID NO:10.

In another embodiment, bases 940 to 955 of the wild type L. cruciata luciferase, i.e. ATTGCATCTGGCGGAG herein SEQ ID NO:11 are changed in the COS luciferase to ATCGCCAGCGGCGGAG herein SEQ ID NO:12.

In another embodiment, bases 1148 to 1163 of the wild type L. cruciata luciferase, i.e. CTTTAGGTCCTAACAG herein SEQ ID NO:13 are changed in the COS luciferase to GCCATCATCATCACC herein SEQ ID NO:14.

In another embodiment, bases 11.56 to 1171 of the wild type L. cruciata luciferase, i.e. CCTAACAGACGTGGAG herein SEQ ID NO: 15 are changed in the COS luciferase to ATCACCCCCGAGGGCG herein SEQ ID NO:16.

In another embodiment, bases 1159 to 1174 of the wild type L. cruciata luciferase, i.e. AACAGACGTGGAGAAG herein SEQ ID NO:17 are changed in the COS luciferase to AACAGACGGGGCGAAG herein SEQ ID NO:18.

In another embodiment, bases 1171 to 1186 of the wild type L. cruciata luciferase, i.e. GAAGTTTGTGTTAAAG herein SEQ ID NO:19 are changed in the COS luciferase to CGACGACAAGCCTGGA herein SEQ ID NO:20.

In a particular embodiment, the corresponding branchpoint sequences for the above cryptic splice sites in the wild type L. cruciata luciferase SEQ ID NO:1, are also altered to further suppress the splicing potential.

Palindromic sequences tend to have an adverse effect on translational efficiency and/or mRNA stability. The degree of these effects are generally directly related to the stability of the loop structures formed by these palindromic motifs. Accordingly, one embodiment of the present invention includes reducing the number of palindromic motifs. In a particular embodiment, palindromic motifs are altered by one or more nucleotides without altering the encoded luciferase enzyme activity and preferably without altering the amino acid sequence.

In a particular embodiment, a palindromic pair of motifs at bases 1087 to 1095 and 1218 to 1226 of the wild type L. cruciata luciferase, ie. GCTTCTGGA and TCCAGAAGC, respectively are changed in the COS luciferase to GCCAGCGGC and CCCCGAGGC, respectively.

In a particular embodiment, a palindromic pair of motifs at bases 1151 to 1158 and 1185 to 1192 of the wild type L. cruciata luciferase, ie. TAGGTCCT and AGGACCTA, respectively are changed in the COS luciferase to TGGGCCCC and GGGCCCCA, respectively.

In a particular embodiment, a palindromic pair of motifs at bases 255 to 264 and 350 to 359 of the wild type L. cruciata luciferase, ie. AAACTGTGAA and TTCACAGTTT, herein SEQ ID NO: 21 and SEQ ID NO:22 respectively are changed in the COS luciferase to GAACTGCGAG and TGCACAGCCT herein SEQ ID NO:23 and SEQ ID NO:24, respectively.

In a particular embodiment, a palindromic pair of motifs at bases 1381 to 1389 and 1508 to 1516 of the wild type L. cruciata luciferase, ie. TTGCAACAT and ATGTTGCAA, respectively are changed in the COS luciferase to CTGCAGCAC and ACGTCGCCA, respectively.

In a particular embodiment, a palindromic pair of motifs at bases 235 to 242 and 883 to 890 of the wild type L. cruciata luciferase, ie. AGAATTGC and GCAATTCT, respectively are changed in the COS luciferase to CGGATCGC and GCCATCCT, respectively.

In a particular embodiment, a palindromic pair of motifs at bases 445 to 452 and 740 to 747 of the wild type L. cruciata luciferase, ie. AAAACCAT and ATGGTTTT, respectively are changed in the COS luciferase to AAGACCAT and ACGGCTTC, respectively.

The wild type Luciola cruciata sequence incorporates several negatively cis-acting motifs that hamper expression in mammals are found in the wild-type sequence. In a particular embodiment of the present invention, the modified sequence contains no negative cis-acting sites (such as splice sites, poly(A) signals, etc.) which would negatively influence expression in mammalian cells.

The wild type Luciola cruciata sequence has a GC content that is quite low compared to mammalian sequences, which facilitates quick mRNA turnover. In another embodiment, the GC-content of the modified luciferase sequence is increased from about 37% to about 62%, prolonging mRNA half-life. Codon usage was adapted to the bias of Homo sapiens resulting in a high CAI (codon adaptation index) value of 0.97, in comparison to 0.62 for the wild-type sequence. Accordingly, the optimized gene provides high and stable expression rates in Homo sapiens or other mammalian cell types.

The codon usage alterations generally lead to an increase the translation efficiency of the messenger RNA in a mammalian cell. It is a feature of the present invention that mRNA transcribed from the modified luciferase gene is more stably present in mammalian cells. This leads to enhanced levels of mRNA and results in greater expression of the luciferase protein. In a particular embodiment of the present invention, the level of mRNA is increased by 10% to 200% compared to expression of the native gene in the same cell. The codon optimization modifications are preferably incorporated such that resulting modified enzyme activity is not altered and most preferably that the amino acid sequence is not altered, except for desired changes described herein.

Many organisms display a bias for use of particular codons to code for addition of a specific amino acid in a growing peptide chain. Codon biases for differences in codon image between organisms often correlate with the efficiency of translation of messenger RNA (mRNA), which in turn is believed to result from the properties of the codons being translated and the availability of particular transfer RNA (tRNA) molecules to be used in translation of the mRNA into protein. The predominance of selected tRNAs in a cell is generally a reflection of the codons used most frequently in peptide synthesis.

Codon usage in highly expressed mammalian genes are as follows:

[AminoAcid Codon Fraction] Gly GGG 0.15 Gly GGA 0.18 Gly GGT 0.21 Gly GGC 0.46 Glu GAG 0.68 Glu GAA 0.32 Asp GAT 0.38 Asp GAC 0.62 Val GTG 0.54 Val GTA 0.08 Val GTT 0.14 Val GTC 0.25 Ala GCG 0.14 Ala GCA 0.13 Ala GCT 0.29 Ala GCC 0.44 Arg AGG 0.14 Arg AGA 0.13 Ser AGT 0.10 Ser AGC 0.25 Lys AAG 0.75 Lys AAA 0.25 Asn AAT 0.26 Asn AAC 0.74 Met ATG 1.00 Ile ATA 0.06 Ile ATT 0.26 Ile ATC 0.67 Thr ACG 0.09 Thr ACA 0.18 Thr ACT 0.23 Thr ACC 0.50 Trp TGG 1.00 End TGA 0.30 Cys TGT 0.46 Cys TGC 0.54 End TAG 0.16 End TAA 0.53 Tyr TAT 0.35 Tyr TAC 0.65 Leu TTG 0.10 Leu TTA 0.03 Phe TTT 0.35 Phe TTC 0.65 Ser TCG 0.07 Ser TCA 0.08 Ser TCT 0.20 Ser TCC 0.31 Arg CGG 0.11 Arg CGA 0.05 Arg CGT 0.17 Arg CGC 0.40 Gln CAG 0.82 Gln CAA 0.18 His CAT 0.35 His CAC 0.65 Leu CTG 0.56 Leu CTA 0.05 Leu CTT 0.08 Leu CTC 0.18 Pro CCG 0.16 Pro CCA 0.19 Pro CCT 0.30 Pro CCC 0.35 The codon bias in the Gene is different to the highly expressed mammalian genes. Of the codons that potentially encode a particular amino some are very rarely used.

By the standard set forth in the preceding paragraph, the wild type Luciola cruciata sequence uses codons rarely used in mammalian systems with a high frequency. To have the most impact the most rarely used codons in highly expressed mammalian genes are preferably changed. In one embodiment of the present invention, at least about 90% of the rarely used codons found in the wild type sequence are altered to more preferred codons for the corresponding amino acid.

For example, the codon TTA is used to encode leucine in only 3% of cases in highly expressed mammalian systems, but is seen in the wild type luciferase of SEQ ID NO:1 at positions 87-89, 246-248, 339-341, 360-362, 405-407, 720-722, 774-776, 801-803, 828-830, 906-908, 933-935, 963-965, 1032-1034, 1152-1154, 1329-1331, 1368-1370, and 1542-1544. In one embodiment of the present invention, each of these positions is changed to CTG, which is a more commonly used in mammalian systems, thus optimizing the nucleic acid sequence for expression in mammals without changing the amino acid sequence. A preferred altered Luciola cruciata Luciferase gene is one where at least about 70%, 80%, 90%, 95%, 99% or 100% of codons are thus optimized for expression in a particular cell system. A specific embodiment of the present invention is the codon optimized and stabilized (COS) Luciferase set forth in SEQ ID NO:3

In another embodiment of the present invention, it is anticipated that conservative amino acid substitutions might be made throughout the enzyme without adversely altering the enzyme activity. One or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity, which acts as a functional equivalent, resulting in a silent alteration.

Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, praline, phenylalanine, tryptophan and methionine. Amino acids containing aromatic ring structures are phenylalanine, tryptophan, and tyrosine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

Particularly conservative amino acid substitutions are: (a) Lys for Arg or vice versa such that a positive charge may be maintained; (b) Glu for Asp or vice versa such that a negative charge may be maintained; (c) Ser for Thr or vice versa such that a free OH can be maintained; (d) Gln for Asn or vice versa such that a free NH₂ can be maintained; (e) Ile for Leu or for Val or vice versa as roughly equivalent hydrophobic amino acids; and (f) Phe for Tyr or vice versa as roughly equivalent aromatic amino acids. However it will be understood that less conservative substitutions may still be made without affecting the activity of the resulting luciferase enzyme.

In a particular embodiment of the present invention, the amino acid encoded at nucleotide position 875-877 in the wild-type sequence, SEQ ID NO:1 is changed from Ser(S) to Tyr(Y). This nucleic position corresponds with position 286 of the wild-type protein sequence, SEQ ID NO:2. This modification was found to have the surprising effect of making the resulting protein >100-fold more stable after 1 hour and >1000-fold more stable after 2 hours at 37° C. The modified luciferase also demonstrated greater thermostability than wild-type protein at room temperature. The substitution of Tyr for Ser at this position was also shown to have the surprising effect of shifting the emitted light from blue to red (from 582 nm to 619 nm (pH 6)). The present invention also anticipates similar conservative amino acid substitutions at nucleotide position 875-877, including substituting Tyr, Lys, Leu, or Gln for Ser.

It will be understood that the invention also encompasses a method of using the modified luciferase gene as a marker gene in live cells, wherein the nucleic acid molecules encoding the modified luciferase gene are provided in an expression vector with appropriate cis- and trans-acting expression elements and thereby provide cells expressing the modified luciferase gene that produce the modified enzyme intracellularly.

The modified luciferase of the present invention might be incorporated as part of a fusion protein. Additionally the invention encompasses a cloning vehicle having a sequence encoding the modified luciferase gene.

The luciferase gene will typically be positioned operably linked to a promoter. Preferably the promoter is a mammalian promoter, and may be selected from one of the many known mammalian promoters. In the context of this invention the term luciferase gene refers to the open reading frame encoding the modified luciferase protein.

Additionally other nucleotide motifs might be introduced to enhance transcription and/or translation such as a Kozak consensus sequence or transcriptional enhancers.

The present invention describes a plasmid vector for expression in mammalian cells, a bacterial vector for expression in plant cells, but also contemplates a retroviral vector or a lentiviral vector, that includes the modified luciferase gene, or a cell carrying the modified luciferase gene.

The examples below are given so as to illustrate the practice of this invention. They are not intended to limit or define the entire scope of this invention.

EXAMPLES Example 1 Construction of the Modified Luciola cruciata Luciferase Gene

The synthetic COS luciferase gene, SEQ ID NO:3, was assembled from synthetic oligonucleotides and/or PCR products. The fragment was cloned into pMK (kanR) using. KpnI and SacI restriction sites. The plasmid DNA was purified (Pure Yield™ Plasmid Midiprep, Promega) from transformed bacteria and concentration determined by UV spectroscopy. The final construct was verified by sequencing. The sequence congruence within the used restriction sites was 100%.

Example 2 Subcloning of the Modified Luciola cruciata Luciferase Gene into the pCMV and pSV40 Vectors

The synthetic COS luciferase assembled in Example 1 was excised from pMK cloning vector using flanking XhoI and NotI restriction enzymes (Fast Digest, Fermentas). The excised fragment was gel-purified (GenElute Gel Extraction Kit, Sigma) and quantitated using MassRuler™ DNA Ladder Mix (Fermentas). The excised gene was subcloned into both pCMV and pSV40 Mammalian Expression Vectors using corresponding XhoI and Nod restriction sites. The completed pCMV construct was named pDC57. The completed pSV40 construct was named pDC99.

Example 3 Subcloning of the Modified Luciola cruciata Luciferase Gene into the pNosdc Binary Vector for Expression in Plants

The synthetic COS luciferase assembled in Example 1 was amplified using the Polymerase Chain reaction. Amplification was performed with primers including XmaI and SacI restriction sites. The ends of the amplified fragment were cut with XmaI and SacI restriction enzymes (New England Biolabs) and the fragment was gel-purified (GenElute Gel Extraction Kit, Sigma) and quantitated using MassRuler™ DNA Ladder Mix (Fermentas). The amplified fragment was subcloned into the pNosdc binary vector for transformation of plants via Agrobacterium tumefaciens. The completed construct was named pNosdcCOS.

Example 4 Transfection of Mammalian Cells with the Modified Luciola cruciata Luciferase Vectors pDC57 and pDC99

NIH 3T3 cells (murine tumor fibroblasts) were grown to 80% confluence in 100 mm tissue culture plates. Cells were transfected with either pDC57 or pDC99 using Lipofectamine and PLUS reagents (Invitrogen).

Example 5 Analysis of Luciferase Expression Levels using the pDC99 Vector and Comparison to the Luciferase Expression Using the Photinus pyralis luciferase Vector pSV40-GL3 in Mammalian Cells

Transfected NIH 3T3 cells prepared in Example 4 were lysed using a lysis buffer comprised of 25 mM Tris-phosphate (pH 7.8), containing 10% glycerol, 1% Triton X-100, 1 mg/ml BSA, 2 mM EGTA and 2 mM DTT. Cells were washed with 1× Phosphate Buffered Saline, and lysis buffer (1 mL) was added to surface of plate. Plate was incubated for 30 mins, and lysate was collected. Additionally, NIH 3T3 cells were transfected with pSV40-GL3, a construct containing wild type luciferase from Photinus pyralis, as per the method in Example 4 and lysed using the above method. As a negative control, untransfected NIH 3T3 cells were also lysed by the above method.

Cell lysates were diluted using lysis buffer, and added in triplicate to wells of a solid white 96-well plate (Costar). Added to cell lysates was a reagent containing 1 mM D-luciferin and 2 mM ATP in a buffer comprised of 25 mM Glycylglycine, 15 mM MgSO4, 4 mM EDTA, 15 mM Potassium phosphate pH 7.8, 1 mM DTT, and 1 mM Coenzyme A.

Luminescence was recorded using a Perkin-Elmer HTS7000 Plus Bio Assay Reader (200 ms integration time). Results of these analyses are shown in FIG. 4.

Example 6 Analysis of the Thermal Stability of the Modified Luciola cruciata Luciferase Protein Versus Wild Type Protein

Cell lysates from NIH 3T3 cells transfected with pDC99 and pSV40-GL3 (transfected according to method in Example 4), as well as untransfected cells were prepared as described in Example 5a. Luminescence of each sample was recorded as described in Example 5a to obtain a baseline value of enzyme activity. Portions of each sample were then incubated in water baths at 37° C., 42° C., and 55° C. A portion of each sample was also incubated at ambient room temperature (25° C.). At 1 hour and 2 hour intervals, aliquots of each temperature-incubation were removed and assayed for activity using the method described in Example 5a. Results of these analyses are shown in FIG. 5.

Example 7 Isolation of the Modified Luciola cruciata Luciferase Protein from Bacterial Culture

Escherichia coli (strain JM109) harboring a plasmid vector containing a Histidine tag (such as pDEST17 (Invitrogen), pET-14b (Novagen and pQE (Qiagen)) fused to the codon optimized and stabilized luciferase gene (COS) are grown to an OD600 of 0.2 by incubation at 37° C. with vigorous shaking in 250 mL LB Broth containing the appropriate selection antibiotic. Bacterial cells are pelleted by centrifugation at 5,000×g, and the pellet is resuspended in a bacterial cell lysis buffer, such as CellLytic B (Sigma Prod. No. B7435). The suspension is incubated for 15 rains to extract soluble proteins, and then centrifuged at >15,000×g for 10 mins to pellet insoluble debris. The lysate is applied to an affinity column (such as HIS-Select, Sigma Prod. No. H7787) equilibrated with 0.1M sodium phosphate, 8M urea, pH 8.0 (equilibration buffer). Impurities are removed by washing the column several times with equilibration buffer. The His-tagged COS protein is eluted from the column using an acidic buffer, such as 0.1 M sodium phosphate, 8 M urea, with a pH in the 4.5-6.0 range. The eluate contains the recombinant codon optimized and stabilized luciferase protein. The purified protein is then dialyzed against H2O and lyophilized. The lyophilized protein is dissolved in reaction buffer (25 mM Glycylglycine, 15 mM MgSO4, 4 mM EDTA, 15 mM Potassium phosphate pH 7.8, 1 mM DTT, and 1 mM Coenzyme A) or dH₂O and assayed by adding a reagent containing 1 mM D-luciferin and 2 mM ATP in reaction buffer.

Luminescence is recorded using a Perkin-Elmer HTS7000 Plus Bio Assay Reader (200 ms integration time).

Example 8 Transfection of Plants with Codon Optimized and Stabilized Luciferase (COS)

Agrobacterium tumefaciens are transfected with pdcNosCOS according to freeze-thaw protocol previously described (D. Weigel, J. Glazerbrook, pp. 125-126 (2002)). Arabidopsis thaliana (strain CS-20) are transfected by the floral dip method using the aforementioned transfected Agrobacterium, using the protocol described previously (D. Weigel, J. Glazerbrook, pp. 129-130 (2002)). Seedlings are selected on Murashige and Skoog Agar plates containing 50 μg/mL kanamycin, as described previously (D. Weigel, J. Glazerbrook, pp. 131-132 (2002)).

Protein is extracted from plant tissue according to the following procedure: Tissue is lyophilized and ground into a fine powder in a mortar. The powder is placed in a microcentrifuge tube and suspended in reaction buffer (25 mM Glycylglycine, 15 mM MgSO4, 4 mM EDTA, 15 mM Potassium phosphate pH 7.8, 1 mM DTT, and 1 mM Coenzyme A) by vortexing. The tube is incubated at 10 mins at room temperature to solubilize proteins, followed by centrifugation at >15,000×g to pellet solid material. The supernatant is transferred to a fresh tube, and added in triplicate to wells of a solid white 96-well plate (Costar). Added to tissue extracts is a reagent containing 1 mM D-luciferin and 2 mM ATP in a buffer comprised of 25 mM Glycylglycine, 15 mM MgSO4, 4 mM EDTA, 15 mM Potassium phosphate pH 7.8, 1 mM DTT, and 1 mM Coenzyme A.

Luminescence is recorded using a Perkin-Elmer HTS7000 Plus Bio Assay Reader (200 ms integration time). 

1-9. (canceled)
 10. An isolated protein encoded by a nucleic acid molecule comprising the nucleic acid sequence as set forth in SEQ ID NO:3.
 11. The isolated protein of claim 10, wherein said protein comprises the amino acid sequence as set forth in SEQ ID NO:4.
 12. The isolated protein of claim 10 wherein said protein is produced by a method comprising culturing, in a medium, a microorganism belonging to the genus Escherichia having inserted therein a nucleic acid sequence encoding said protein and collecting the luciferase protein from the culture.
 13. The isolated protein of claim 10, wherein said protein exhibits bioluminescence in the presence of D-luciferin at a wavelength between about 590 nm and about 620 nm.
 14. A kit for detecting ATP comprising: A. the isolated protein of claim 10; and B. at least one ATPase inhibitor, wherein the combination of said protein and said ATPase inhibitor forms a composition for detecting ATP in a sample.
 15. An isolated amino acid molecule comprising the amino acid sequence as set forth in SEQ ID NO:4.
 16. An isolated nucleic acid molecule comprising a modified version of SEQ ID NO:1, wherein: A. such modifications consist of i. alteration of at least one palindromic sequence, ii. alteration of at least one cryptic splice acceptor site, iii. alteration of at least one cis-acting motif, iv. increasing GC content compared to native SEQ ID NO:1 by at least 10%, v. removing at least one RNAse cleavage motif, and vi. alteration of nucleotides 875-877 to encode an amino acid selected from the group consisting of Tyr, Lys, Leu and Gln; and B. wherein said isolated nucleic acid molecule encodes a protein that exhibits bioluminescence in the presence of D-luciferin at a wavelength between about 590 nm and about 620 nm. 